Neuropathic Pain: The Sea Provides A New Hope of Relief
A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system. Currently this form of pain is very poorly controlled by the usual analgesics (aspirin like drugs (NSAIDS) or even opiods like morphine) and novel treatments are urgently required.
Source: Science Daily
Less sweat, more neuropathy
A novel technique to measure the density of autonomic nerve fibers that innervate sweat glands could help determine the extent and pregression of peripheral neuropathy. "We could already quantify small sensory fibers using intra-epidermal nerve fiber density (IENFD) analysis of skin biopsies but, until now, had no means to quantify autonomic nerve fibers...." explains Roy Freeman, MD (Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Boston, MA)
Source: Nature News/Neurology
Study May Redefine How A Chronic Autoimmune Disease Is Diagnosed
New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is diagnosed.
Source: Science Daily
Capsaicin Patch Reduces Pain From HIV Neuropathy
Treatment with high-concentration capsaicin dermal patch is a safe and well tolerated means of reducing pain associated with HIV-related neuropathy, the results of a pilot study suggest. Up to 62% of HIV-infected patients develop distal sensory polyneuropathy (DSP) that is either due to the disease itself or to antiretroviral therapy, according to the report in the Journal of Pain and Symptom Management for March.
Capsaicin: Risks and Benefits
Capsaicin is currently used in topical form for postherpetic neuralgia. This medication is also used on the skin to relieve pain conditions such as arthritis, psoriasis, or diabetic neuropathy. With chronic exposure to capsaicin, neurons are depleted of neurotransmitters, and this leads to a reduction in sensation of pain and a blockage of neurogenic inflammation.
Source: US Pharmacist
Lyme Disease is Spreading in Canada, And Physicians Are Crucial In Helping Minimize Its Impact
Lyme disease is transmitted by ticks which feed on animal or human hosts. It begins with a skin lesion that expands, and if left untreated, can result in facial palsy, meningitis, cardiac issues and progress to nerve damage (peripheral neuropathy) and inflammation of the brain and spinal cord (encephalomyelitis).
Source: Science Daily
Neuropathy Patients, Doctors, and Medical Professionals Rally in Sacramento to Demand...
Neuropathy Action Awareness Day, sponsored by the Neuropathy Action Foundation (NAF) and the Alliance for Plasma Therapies (APT), gathered patients, physicians and medical professionals and respresentatives from other organizations including The Neuropathy Association, Foundation for Peripheral Neuropathy and International Pemphigus and Phemphigoid Foundation to learn about neuropathy and to promote awareness of the disease.
The Immune Deficiency Foundation (IDF) is requesting your participation in a ground-breaking survey. Thousands of people in the primary immunodeficiency community depend on immunoglobulin replacement therapy (IVIG, SCIG or IM) to help ward off infections. However, immunoglobulin replacement therapy (Ig therapy) is used for many different conditions, and there are thousands more individuals in the United States who depend on access to immunoglobulin therapy to treat their illnesses. Much like our own community, many patients with these other diseases have experienced difficulty maintaining consistent access to their prescribed Ig therapy.
For the first time ever, IDF is joining with a group of other patient organizations to help give Ig therapy users “one-voice” in our Nation’s Capitol. IDF is asking you to participate in the survey Patient Experiences with Immunoglobulin Therapy to assist in collecting important data for our collective efforts on Capitol Hill.
You have received this invitation because the IDF has identified someone in your family as being diagnosed with a primary immunodeficiency disease. The survey should take only 10-15 minutes to complete.
All of your answers are completely confidential and all data will be presented together so that none of your answers can be tied back to you individually. Your participation is completely voluntary, but it is extremely important to our community.
Please take a few moments now to fill out the survey by clicking on the link below:
You may receive more than one request to participate in this survey (through an e-mail inviting you to participate in a web-based survey or perhaps a second mailing), but you only need to complete the survey once. If you have any questions, please contact Chris Scalchunes, Director of Survey Research at IDF at: 1.800.296.4433.
Thank you for your time and commitment to our community.